Life Science Investing Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
Life Science Investing Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
Life Science Investing Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist for Central Disorders of Hypersomnolence
Life Science Investing Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
Life Science Investing Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
Life Science Investing Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
Life Science Investing Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
Life Science Investing Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
